Aethlon Medical
AEMD
#10974
Rank
$8.71 M
Marketcap
$5.43
Share price
-2.16%
Change (1 day)
24.83%
Change (1 year)
Categories

P/E ratio for Aethlon Medical (AEMD)

P/E ratio as of November 2026 (TTM): -0.0717

According to Aethlon Medical 's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -0.0717147. At the end of 2022 the company had a P/E ratio of -0.0544.

P/E ratio history for Aethlon Medical from 2001 to 2023

PE ratio at the end of each year

Year P/E ratio Change
2022-0.0544-86.41%
2021-0.4000-15.95%
2020-0.47591551.22%
2019-0.0288-95.57%
2018-0.6500160.01%
2017-0.2500-56.19%
2016-0.5707-57.14%
2015-1.3339.45%
2014-0.954789.39%
2013-0.504158.6%
2012-0.3179128.86%
2011-0.1389-19.31%
2010-0.1721-64.43%
2009-0.4839168.33%
2008-0.1803-72.35%
2007-0.652254.59%
2006-0.421958.52%
2005-0.2661-38.26%
2004-0.431047.58%
2003-0.292176.71%
2002-0.1653-49.05%
2001-0.3244

P/E ratio for similar companies or competitors

Company P/E ratio P/E ratio differencediff. Country
PerkinElmer
PKI
15.0-20,969.64%๐Ÿ‡บ๐Ÿ‡ธ USA
Pacific Biosciences
PACB
-5.21 7,163.92%๐Ÿ‡บ๐Ÿ‡ธ USA
Coherent Corp.
COHR
42.3-59,138.38%๐Ÿ‡บ๐Ÿ‡ธ USA
Bruker
BRKR
-56.6 78,798.47%๐Ÿ‡บ๐Ÿ‡ธ USA
Accelerate Diagnostics
AXDX
-0.0192-73.21%๐Ÿ‡บ๐Ÿ‡ธ USA
Inovio Pharmaceuticals
INO
-0.7924 1,004.86%๐Ÿ‡บ๐Ÿ‡ธ USA

How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.